Why Keytruda Is Avoided in Pregnancy
Keytruda (pembrolizumab), a PD-1 inhibitor used for cancers like melanoma and lung cancer, carries significant risks during pregnancy. It can cross the placenta, potentially harming fetal development by disrupting immune tolerance needed for a healthy pregnancy. Animal studies show embryo-fetal toxicity, including skeletal abnormalities and reduced fetal weight, at doses similar to human levels. No adequate human data exist, but experts classify it as contraindicated in pregnancy due to these risks.[1][2]
Who Specifically Should Avoid It
- Pregnant women: All should avoid Keytruda, regardless of trimester, as it may cause fetal loss, birth defects, or preterm delivery. Label warns against use in known or suspected pregnancy.[1]
- Women of childbearing potential: Those not using effective contraception during treatment and for at least 4 months after the last dose, due to Keytruda's 22-day half-life and prolonged effects.[1][2]
- Fertile male patients: Men taking Keytruda whose partners are pregnant or could become pregnant should use condoms during treatment and for 4 months post-treatment to prevent exposure via semen.[1]
Fertility and Reproductive Risks
Keytruda may impair fertility in both sexes. Women report ovarian failure in some cases, and men face reduced sperm counts. Patients planning pregnancy should discuss cryopreservation options pre-treatment.[1][2]
What Happens If Exposed Unintentionally
Limited case reports show adverse outcomes like spontaneous abortion or congenital anomalies, but data is sparse. Women should stop Keytruda immediately upon pregnancy confirmation and enroll in the Merck Pregnancy Registry (1-877-888-4231) for monitoring.[1]
Safer Alternatives During Pregnancy
No immunotherapy like Keytruda is proven safe in pregnancy. Options depend on cancer type and stage:
- Chemotherapy (e.g., certain regimens in second/third trimesters).
- Surgery or radiation, if feasible.
- Delaying non-urgent treatment until postpartum.
Consult maternal-fetal medicine specialists; decisions weigh maternal survival against fetal risks.[2][3]
Ongoing Monitoring and Guidelines
FDA pregnancy category not assigned (uses Risk Summary). NCCN and ASCO guidelines recommend against PD-1 inhibitors in pregnancy, favoring less toxic therapies. Verify insurance coverage for fertility preservation.[2]
Sources
[1]: Keytruda Prescribing Information (Merck)
[2]: Drugs.com - Keytruda Pregnancy Warnings
[3]: FDA Label - Pembrolizumab